CNM-Au8 in Amyotrophic Lateral Sclerosis

Overview of attention for article published in JAMA: Journal of the American Medical Association, February 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 8 news outlets
blogs: 4 blogs
twitter: 10 X users
facebook: 3 Facebook pages

video: 1 YouTube creator
bluesky: 4 Bluesky users
podcasts: 2 podcasts

Readers on

mendeley: 30 Mendeley

So far, Altmetric has seen 10 news stories from 8 outlets.

Clene to Submit Application for CNM-Au8 as Potential ALS Treatment

Neurology Live, 17 Nov 2025

According to a recent company update, Clene Nanomedicine plans to submit a new drug application (NDA) in the first quarter of…

Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

Alzforum, 21 Mar 2025

Writing Committee for the HEALEY ALS Platform Trial, Shefner JM, Oskarsson B, Macklin EA, Chibnik LB, Quintana M, Saville BR…

CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

Alzforum, 21 Mar 2025

Writing Committee for the HEALEY ALS Platform Trial, Berry JD, Maragakis NJ, Macklin EA, Chibnik LB, Quintana M, Saville BR…

Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.

Alzforum, 14 Mar 2025

Writing Committee for the HEALEY ALS Platform Trial, Andrews J, Paganoni S, Macklin EA, Chibnik LB, Quintana M, Saville BR…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 6 additional news stories.